News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Is This One Drug Enough To Revive Hope In Eli Lilly and Company (LLY)'s Pipeline?


3/5/2014 8:15:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Eli Lilly & Co snagged a win (or at least avoided a loss) this week, announcing that its projected blockbuster GLP-1 agonist diabetes medication dulaglutide was comparable to current lead treatment Victoza (liraglutide) by Novo Nordisk .

Help employers find you! Check out all the jobs and post your resume.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES